



MARVIN YEE





- 1. Introduction Chairman
- 2. Apologies
- 3. Managing Director's Address
- 4. Business of the ASM
- Resolution 1
- 5. General Business and Questions





MARVIN YEE CHAIRMAN

Marvin is the principal of Crown
Financial Services (CFS) and is a partner
of Crown Private, a global investment
syndicate with investments in over 95
countries. Marvin sits on a number of
company boards in multiple countries
and brings a wealth of knowledge in
governance and board processes.



DAN CASEY MANAGING DIRECTOR

Dan is a co-founder of GFI and has a background in project management and civil engineering within the civil construction sector. He has over 15 years industry experience, both in New Zealand and abroad. Dan is experienced in all facets of the project lifecycle of large-scale developments and capital works and has previously directly managed multiple and concurrent project portfolios up to the value of \$30 million.



SIMON MCARLEY SIMON MCARLEY

Simon is a lawyer by training who specialises in corporate governance and risk. After almost 20 years in private practice, Simon took up regulatory positions with NZX as acting Head of Regulation and the (then) Securities Commission as acting Director Primary Markets. Simon went on to join the Serious Fraud Office (SFO) as General Manager Capital Markets and Corporate Fraud.



KIRSTEN TAYLOR INDEPENDENT DIRECTOR

Kirsten Taylor is an experienced company owner, CEO, and Board Member. Kirsten is the founder of SleepDrops International, the top selling sleep category brand in NZ pharmacies and health stores and winner of multiple awards including Best Emerging Business at the Westpac Business Awards in 2014.







ANNUAL MEETING 29 SEPT 2023 (29/09/2023)

Vote Totals - Based on the first resolution

Securities On Issue	109,857,152
---------------------	-------------

Valid Securities Voted - (For, Against, Discretionary) 18,652,763

Valid Securities Voted (%)

Total Lodged 53

Vote Details

Resolution	Vote type	Voted	%	% of all securities
1 - AUTHORISE DIRECTORS TO FIX AUDITOR FEES.	For	17,640,361	94.57	16.06
	Against	137,021	0.73	0.12
	Discretionary	875,381	4.69	0.80
	Board	466,101	2.50	0.42
	Non-Board	409,280	2.19	0.37
	Abstain	744,783	N/A	0.68

Source of Vote

	Keyed	Scanned	Intermediary Online	Proxymity	InvestorVote	InvestorVote Mobile	Other
Votes	12,728,687	0	0	0	6,137,895	530,964	0
No. of Proxies	3	0	0	0	32	18	0







DAN CASEY






GFI AIMS TO BE A GLOBALLY RECOGNISED NZ MEDICINAL CANNABIS BRAND

Founded in 2018, GFI is emerging as a global leader in the sustainable production of medicinal cannabis

GFI also has operations spanning into biotechnology, industrial hemp, hemp food and body care spaces

Their company-owned, on-site hydro station allows for direct supply of low-cost, renewable power to their cultivation's facility

Proudly New Zealand based and branded, GFI is a Toitū Carbon net zero certified organisation, and is New Zealand's only certified B Corp medicinal cannabis business







GREENFERN'S OPERATIONAL PRIORITIES

	CURRENT	FUTURE	
NEW ZEALAND CULTIVATION	 We have recently commissioned our new Stage 2 Cultivation, Drying and Packaging Facility. Over 250m2 of indoor cultivation footprint 	 Feasibility into GMP finishing to our Drying and Packaging Rooms New cultivation buildings on existing site Stage 3 much larger commercial cultivation and finishing facility on neighbouring land 	
MARKET EXPANSION TO THE PROPERTY OF THE PROPER	 Harness our current 2-year offtake agreement into Europe for GACP finished flower products Continue to develop and refine unique and specialised genetics and cultivation techniques 	 Take our indoor grown medicinal cannabis flower to new markets such as Australia, the UK and other EU countries Release our own branded flower products to our current SKU lines in Australia and New Zealand 	
ENVIRONMENTAL AND CORPORATE RESPONSIBILITY	 Working closely with Iwi, Hapu and surrounding stakeholders to bring them on our journey with us Ratification by having third party ESG accreditations such as Toitu and Bcorp 	Continue to set example and lead in sustainable and ethical medicinal cannabis operations helping NZ be a leader in this space	
TARANAKI REGION	Currently one of only a small number of listed Taranaki companies	 Expansion and growth within the region creating jobs and opportunities in this sector and helping grow the Taranaki regional economy 	



WE HAVE COME A LONG WAY:

MAY 2021

First Toitū
carbon netzero
certified cannabis
organisation in NZ

SEP 2021

Master Services
Agreement signed
with Australian
company
Cannvalate Pty Ltd

NOV 2021

GFI is announced as the winner of the Australian Cannabis & Hemp Industry Green Award

DEC 2021

GFI enter into a heads of agreement contract with Vortex Group limited to upgrade hydro power station

MAR 2022 J

GFI becomes
New Zealand's first
certified medicinal
cannabis B-Corp
Company

JUN 2022

Binding offtake agreement secured for overseas supply of medicinal cannabis

SEPT 2022

GFI has been awarded a further **Bioresource Processing Alliance**(BPA) grant.

AUG 2023

Two new cultivation rooms commissioned with first room in new facility populated with over 250 medicinal cannabis plants and pending harvest



DEC 2020

GFI purchases
hydropower
generation
plant at
Normanby,
Taranaki

JUN 2021

Bio-Resource
Processing Alliance
(BPA) grant to
develop hemp seed
by-products into
more value-added
products with
partner Hemp
Connect Ltd

OCT 2021

Compliance

listing on

the NZX

main board

GFI Pharma

branded Good

Manufacturing

Practice (GMP)

medicines

in Australia

NOV 2021

MAR 2022

GFI commences
the writing of
clinical trial
protocols in pursuit
of the Australian
OTC low-dose CBD
market with \$250m

JUN 2022

GFI receives
globally-recognised
GACP (Good
Agriculture and
Collection Practice)
certification

AUG 2022

GFI have entered non-binding agreement for "Syndros", one of only Four "FDA" approved cannabinoid medicines.

SEPT 2022

GFI has been awarded a **License to Export Controlled Drugs** by Medsafe.

MAR 2023

Commencement of construction of stage 2 commercial cultivation facility



CULTIVATION OF PHARMACEUTICAL GRADE CANNABIS FOR CURRENT MEDICINAL CANNABIS MARKETS IN NZ AND INTERNATIONALLY

Progress Report

- Government issued commercial cannabis licence successfully renewed in July 2023
- R&D crop in Phase 1 research facility ongoing
- Binding 2-year medicinal cannabis offtake agreement worth up to \$1.6m secured for overseas market
- Development and stabilisation of desired and unique genetics for the overseas market ongoing
- Ongoing discussions with several other medicinal cannabis buyers
- Stage 2 commercial scale facility commissioned and operational from August this year
- Commercial crop ready for export by Q1 2024 pending all regulatory approvals and quality testing requirements

Key Takeaway: GFI is uniquely positioned to leverage critical offtake agreement to take share in a growing market both domestically and globally.








SALE OF GMP MEDICINES IN AUSTRALIA WITH NEW **ZEALAND AS A TARGET MARKET**

Progress Report

- GFI's successful move into the patient acquisition and prescriber space in Australia through partner Cannvalate has yielded strong growth (33% new patient growth MoM, 37% returning)
- Australian TGA/GMP standards are strict, and will assist GFI in working with MedSafe to register existing product formulations in NZ as economies of scale make sense
- Discussions with Australian entities to bring our own NZ cultivated medicinal cannabis flower to Australia and repurpose under GMP licensed facility for repackaging under our own brand label as well as packaged for bulk export globally
- Introduction of our flower products into both the Australian and New Zealand prescriber markets will help strengthen our market share and cover a wider patient base.

Key Takeaway: GFI sees the larger and more advanced Australian market to be a key growth driver and is working towards growing business opportunities in this jurisdiction.

GREENFERN INDUSTRIES AGM 2023




SALE OF SURPLUS HYDROELECTRICITY PRODUCED ON-SITE

Progress Report

- Exclusive Heads of Agreement entered with Vortex Group to negotiate a joint development upgrade of hydropower generation plant at Normanby, Taranaki (purchased by GFI for \$750k in Dec 2020)
- Station generates renewable power to run GFI's onsite cannabis cultivation facility enabling significant cost benefits that provide a meaningful margin advantage relative to GFI's peer group
- Excess power is sold back to the national grid for additional revenue.
- Development is expected to increase generation capacity from 250Kw to ~950Kw and increase asset book value to approximately \$3.5m
- GFI and Vortex will each own a 50% stake in the upgraded asset
- Negotiations ongoing to secure final contract with Vortex Group

Key Takeaway: GFI's onsite hydropower plant is a meaningful differentiator both environmentally and in terms of manufacturing/cultivation costs.









MARVIN YEE





RESOLUTION 1 – AUDITOR FEES AND EXPENSES

Section 207S of the Companies Act provides that, if the auditor is appointed at a meeting of the Company (expressly by resolution or by automatically by operation of section 207T of the Companies Act), the fees and expenses of the auditor must be fixed by the Company at the Meeting or in the manner that the Company determines at the Meeting.

To consider, if thought fit, pass the following ordinary resolution

"That the directors of the Company be authorised to fix the fees and expenses of the Company's auditor."
























THANK YOU

- +64 27 420 2476
- % www.gfi.nz
- Greenfern Industries Video









Disclaimer

Greenfern Industries Limited (GFI) is a New Zealand licensed medicinal cannabis, research and biotechnology company aiming to be a leading producer of medicinal cannabis products and medicines. The information in this presentation is for general information purposes only, and does not constitute, or contain, an offer or invitation for subscription, purchase, or recommendation of securities in GFI for the purposes of the Financial Markets Conduct Act 2013 or otherwise, or constitute legal, financial, tax, financial product, or investment advice This presentation has not been independently verified. Neither GFI nor any of its directors, officers, shareholders, advisors, agents or employees make any representation or warranty as to the accuracy or completeness of the information contained in this presentation and those parties shall have no liability for any statement, opinion, information or matters arising out of, contained in, or for any omissions from, or failure. to correct or update any information in, this presentation or any other communications.

The information provided by GFI in this communication may include forward-looking financial and market scenarios. These scenarios are based on current assumptions, expectations, projections, and other information available to the Company. However, it is important to note that actual outcomes may differ materially from these scenarios due to various factors beyond the Company's control. GFI does not guarantee the accuracy or completeness of these scenarios. Recipients of this information are cautioned not to place undue reliance on these forward-looking statements, as the Company cannot predict with certainty which scenario will ultimately transpire.

transmitted to you in relation to this presentation.

